CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP: 1.Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP: 2.Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP: 3.Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP: 4.MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP: 5.Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP: 6.Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP: 7.Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

Now Viewing

EP: 8.CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP: 9.Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP: 10.Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

1. Dr Ajai Chari to Dr Martin: Let’s dive deeper into the KARMMA-3 study that got ide-cel approved. Dr Martin: Can you please review the KARMMA-3 study design, patient population, and efficacy outcomes including overall survival (OS) data?

Resource Link:

• Ailawadhi S et al. KarMMa-3 Updated Analysis 2024 - online ahead of print
• Rodriguez-Otero P et al. KARMMA-3 NEJM 2023 Idel-cel rrMM.
• Rodiguez-Otero P et al. KarMMa-3 Updated Analysis. ASH 2023 Oral Abstract.

1. Dr Ajai Chari to Dr Callander: Now that we have discussed KARMMA-3, let’s review CARTITUDE-4. Dr Callander: Can you please review the CARTITUDE-4 study design, patient population, and recently presented IMS 2024 CARTITUDE-4 OS data updates

Resource Link

• OA-65 IMS 2024 CARTITUDE 4 or (see page 14)